# Mineralys Therapeutics Inc. (MLYS) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $28.21, market value $2.5 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Mineralys Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 4.5×**. The shares trade at 4.5× book value; book value is a meaningful part of the valuation.

## Profitability
- **Return on equity: -23.9%**. Return on equity is negative because earnings are negative.

## Growth
- **EPS growth (1 yr): 37.4%**. Earnings per share rose 37.4%.

## Financial health
- **Current ratio: 43.76** (quick 43.76). Current assets cover the next year's liabilities 43.76 times.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Mineralys Therapeutics Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): -14.8%** (YTD -22.3%, 3-mo 19.1%). The shares are down 14.8% over twelve months including dividends.
- **From 52-week high: -40.8%** (26.5% above the low). Trading 41% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 60**. An RSI of 60 is neutral.
- **Beta (1 yr): 0.85** (volatility 59%). Beta of 0.85 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=MLYS · Page: https://foliofundamentals.com/stocks/mlys

Not investment advice.